The first integrated multisensor project that allows non-invasive continuous monitoring of blood glucose developed by Banting Labs has just closed its first investment round of 70,000 euros. With this contribution, the company dedicated to technological innovation in the field of health will be able to continue financing the development of the prototype and the management of intellectual property, during the coming months. In addition, the company intends to leverage this investment with public aid such as Startup Capital and NEOTEC.
Banting Labs’ goal is to be able to launch this continuous glucose monitor on the market at the beginning of 2027, according to its CEO, David Reyes. The company, based at the TecnoCampus, has been working on this solution for nearly three years, which arises from the need to improve the quality of life of people living with diabetes.
The idea to promote this project arose from the own experience of a relative of David Reyes, who was diagnosed with type 1 diabetes. “At first we did not know how it would affect him and I, who have always had an entrepreneurial streak, began to look for solutions to control diabetes,” explains Reyes. According to him, they soon realized that current sensors for measuring glucose level detect it in the interstitial fluid, but not directly from the blood. “This gave outdated results that influenced therapeutic decisions,” he comments.
To improve results, the idea arose to create continuous measurement technology capable of showing blood glucose levels in real time. Reyes, who has studied business management and administration at TecnoCampus, joined two other students from the center, engineers Axel Rico and Gabriel de la Ossa, to promote the project.
The project, which was initially called Hoop Diabetes, is the result of exhaustive research and development work, in which cutting-edge technologies, market analysis and deep knowledge of the user have been integrated.
The integrated multisensor that Banting Labs is developing aims to offer real-time readings of blood glucose. This device will provide accurate, real-time measurements of blood glucose levels, with the intention of eliminating the time lag presented by other monitoring devices.
One of the main advantages of this innovation will be the ability to minimize the risk of suffering from hypoglycemia. By providing real-time readings, patients will be able to adjust their treatments more precisely, more accurately calculating the necessary insulin doses and thus reducing the margin of error that comes with traditional monitoring.
Additionally, use of this device may lead to a greater amount of time in the target blood glucose range. In this way, patients will be able to experience longer glycemic stability, which significantly contributes to improving their quality of life and reducing complications associated with type 1 diabetes.
To develop this solution, a combination of different measurement technologies has been used together with a prediction algorithm.
The company is preparing the first clinical trial to validate the portable prototype with which it intends to build a database to model the prediction algorithm.
